Myriad Genetics Acquires Patent on Another Breast Cancer-Linked Gene
By Ayesha Ahmad,
BioNews
| 01. 23. 2012
Myriad Genetics, a leading US molecular diagnostic company, has been granted exclusive rights to an analysis of the RAD51C gene. Mutations of the gene have been associated with an increased risk for hereditary breast and ovarian cancer and the company now hopes to develop a commercial test for RAD51C.
Mark Capone, president of Myriad, said: 'This intellectual property will enhance our ability to provide patients and health care providers important information on a patient's predisposition to hereditary breast and ovarian cancer'.
Read more...
Image via Flickr.
Related Articles
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Rob Stein, NPR [cites CGS' Katie Hasson] | 09.29.2026
Cathy Tie slips on a white lab coat bearing her name and the logo of her startup: Origin Genomics. "Welcome!" she says as she leads an NPR reporter, photographer and videographer on an exclusive tour of Origin's labs located...
By Erik Adams, Sundance | 09.08.2026
The scariest movie playing at the 2026 Sundance Film Festival isn’t about cursed audio recordings or a killer demon disguised as your true love; rather it’s a 110-minute essay film about how a handful of guys obsessed with numbers and...
By Gaia Ghirardi, Arno Van Hootegem & K. Paige Harden , Nature Human Behaviour | 09.21.2026
Embryo screening for behavioural traits is no longer speculative. If you want to become a parent in the USA today, you can pay to use pre-implantation polygenic testing (PGT-P) of in vitro fertilization (IVF)-created embryos. PGT-P promises to optimize offspring...
